What do systematic reviews say?

Summary of findings table ‐ Topical small molecule inhibitors (ruxolitinib) vs placebo

It is very uncertain whether summary of findings table ‐ Topical small molecule inhibitors… changes incidence of serious adverse events compared with placebo (very low certainty).

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  RR 0.33 [0.01, 7.94]
  1 study · 78 participants
  Very low

Summary of findings table ‐ Topical small molecule inhibitors (ruxolitinib) vs placebo

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Topical small molecule inhibitors (ruxolitinib) vs placebo

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs placebo

It is very uncertain whether summary of findings table ‐ Contact immunotherapy (diphencyprone or… changes short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with placebo (very low certainty).

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  RR 1.16 [0.79, 1.71]
  1 study · 99 participants
  Very low

Summary of findings table ‐ Oral classical immunosuppressants (prednisolone or cyclosporine) vs placebo

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 36 participants
  Very low

Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs placebo

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs placebo

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs placebo

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Oral classical immunosuppressants (prednisolone or cyclosporine) vs placebo

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Minoxidil vs placebo

It is very uncertain whether summary of findings table ‐ Topical hair growth stimulants (minoxidil) changes short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with placebo (very low certainty).

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  RR 2.31 [1.34, 3.96]
  2 studies · 202 participants
  Very low

Minoxidil vs placebo

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 304 participants
  Very low

Minoxidil vs placebo

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Minoxidil vs placebo

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Intralesional classical immunosuppresants (betamethasone or triamcinolone) vs placebo

It is very uncertain whether summary of findings table ‐ Intralesional classical… changes short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with placebo (very low certainty).

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  RR 13.84 [0.87, 219.76]
  1 study · 231 participants
  Very low

Oral methotrexate vs placebo

Oral methotrexate may leads to higher primary outcome: complete clinical response (malar/discoid rash) compared with placebo (low certainty).

• Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
  RR 3.57 [1.63, 7.84]
  1 study · 41 participants
  Low

Oral hydroxychloroquine vs placebo

Oral hydroxychloroquine probably leads to lower secondary outcome: clinical flare compared with placebo (moderate certainty).

• Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
  RR 0.49 [0.28, 0.89]
  1 study · 47 participants
  Moderate

Oral hydroxychloroquine vs placebo

• Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Oral hydroxychloroquine vs placebo

• Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Oral hydroxychloroquine vs placebo

Oral hydroxychloroquine showed no clear difference in adverse events: severe compared with placebo (moderate certainty).

• Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
  RR 3.9 [0.19, 78.46]
  1 study · 71 participants
  Moderate

Oral hydroxychloroquine vs placebo

Oral hydroxychloroquine showed no clear difference in adverse events: minor compared with placebo (moderate certainty).

• Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
  RR 1.32 [0.24, 7.19]
  1 study · 47 participants
  Moderate